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Summary
Background: The optimal duration of dual antiplatelet therapy (DAT) in patients undergoing
intracoronary sirolimus-eluting stent implantation remains controversial.Sirolimus-eluting
stent;
Bleeding;
Optimal duration
Objective: To evaluate the clinical effects of long duration DAT in patients undergoing intracoro-
nary sirolimus-eluting stent implantation in daily practice. In addition, to attempt to identify
the optimal duration of DAT after implantation of a sirolimus-eluting stent.
Methods: We retrospectively report on 1293 consecutive patients who underwent successful
intracoronary sirolimus-eluting stent implantation. We analyzed the cumulative incidence of
l myocardial infarction (MI), death from cardiac causes, and thestent thrombosis, non-fata
cumulative incidence of bleeding complications.
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Results: We compared the study end point in patients who received DAT for <6months (n = 1136)
with that for patients who received DAT for >6months (n = 157). The median follow-up period
was 1260± 462 days. Major bleeding occurred in 35 patients and intracranial hemorrhage in 8. In
patients on DAT for >6months, the incidence of any bleedings, major bleedings, and intracranial
hemorrhage was signiﬁcantly increased. On the other hand, there was no signiﬁcant difference
between the two groups in the risk of the primary end points (stent thrombosis, non-fatal MI,
death from cardiac causes, death or MI).
Conclusions: Prolonged DAT for more than 6months was not signiﬁcantly more beneﬁcial than
aspirin monotherapy in reducing the risk of the occurrence of acute MI, stent thrombosis, and
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p = 0.027).
Any bleeding occurred in 48 patients, major bleed-death, although it was associa
© 2011 Japanese College of C
ntroduction
he optimal duration of dual antiplatelet therapy (DAT), i.e.
spirin plus a thienopyridine, is unknown. Current American
ollege of Cardiology/American Heart Association/Society
or Angiography and Interventions guidelines recommend
hat in addition to aspirin, clopidogrel 75mg should be
ontinued for a minimum of 1 year of DAT after implanta-
ion, and some guidelines recommend even longer therapy
1]. Some studies of DAT with clopidogrel plus aspirin
ound a reduction in ischemic events [2,3]. Most recently,
he DECREASE registry [4] has shown that the addition
f cilostazol to aspirin and clopidogrel (triple antiplatelet
herapy) reduced 12-month risks of stent thrombosis and
yocardial infarction (MI) after drug-eluting stent (DES)
mplantation.
On the other hand, some studies have reported that long-
erm use of DAT is likely to increase the incidence of bleeding
vents.
However, these are multicenter registry and random-
zed controlled trial studies wherein the equivalence of
atient clinical backgrounds is validated. It is well known
hat such patients differ from those encountered in daily
ractice.
We therefore evaluated the problems associated
ith long duration DAT in patients undergoing intra-
oronary sirolimus-eluting stent implantation in daily
ractice.
ethods
e analyzed consecutive patients who received a sirolimus-
luting stent (Cypher, Cordis, Miami Lakes, FL, USA) at our
enter between June 1, 2004, and August 31, 2006. Exclu-
ion criteria were contraindication to antiplatelet agents,
nown bleeding disorders, and liver cirrhosis. Patients
eceived aspirin 200mg/day and ticlopidine 200mg/day
r clopidogrel 75mg/day at least 24 h before the pro-
edure. The primary composite end point of this study
as the ﬁrst occurrence of stent thrombosis, non-fatal
I, and death from cardiac causes. MI was deﬁned
s documented non-fatal MI adjudicated by either new
bnormal Q waves or predeﬁned enzymatic changes.
he secondary end point was incidence of bleeding.
leeding complications were divided into major and
inor.
Major bleeding was deﬁned according to the Thromboly-
is in Myocardial Infarction study group criteria [5].
i
o
i
p
pwith an increase in bleeding complications for low-risk patients.
ology. Published by Elsevier Ltd. All rights reserved.
tatistical analysis
ll calculations were analyzed using SPSS 11.0 (SPSS Inc.,
hicago, IL, USA), and p-values <0.05 (2-tailed) were con-
idered signiﬁcant. Continuous variables among groups were
xpressed as means± SD, and were compared by t test. Cat-
gorical data were compared using the 2 test or Fisher’s
xact test. Event-free survival analysis was performed by
he Kaplan—Meier method with log-rank test group com-
arison. Hazard ratios (HRs) and their 95% conﬁdence
ntervals (CIs) were measured by Cox proportional hazard
odels.
esults
e analyzed 1293 consecutive patients who received a
irolimus-eluting stent between June 1, 2004, and August
1, 2006. We compared the study end point in patients
ho received DAT for <6months (n = 1136) with that for
atients who received DAT for >6months (n = 157). The
edian follow-up period was 1260± 462 days. Table 1 shows
he baseline clinical characteristics of all patients and of
he two study groups. The mean age was 67± SD years; 24%
f patients were women, and 45% had medically treated
iabetes.
The age, sex, body mass index, coronary risk factors,
nd rate of acute coronary syndrome were well balanced
etween the two groups. Moreover, past history of MI,
troke, percutaneous transluminal angioplasty, percuta-
eous coronary intervention (PCI), and coronary artery
ypass graft (CABG) were similar between the two groups.
owever, compared with the DAT <6months group, the DAT
6months group had a higher prevalence of left main lesions
7.4% vs. 2.2%, p < 0.001), proximal left ascending artery
esions (31% vs. 21%, p = 0.014), and multivessel lesions (37%
s. 24%, p = 0.001). Furthermore, compared with the DAT
6months group, in the DAT >6months group the lesion was
nﬂated to a higher inﬂation pressure (15.4± 3.34 atm
s. 14.8± 3.29 atm, p = 0.037) and expanded to a
reater extent (3.185± 0.475mm vs. 3.098± 0.446mm,ng occurred in 35 patients, and intracranial hemorrhage
ccurred in 8 patients. In patients on DAT >6months, the
ncidence of any bleeding (HR 3.652; 95% CI, 1.973—6.758;
< 0.001), major bleedings (HR 3.623; 95% CI, 1.763—7.444;
< 0.001), and intracranial hemorrhage (HR 4.545; 95%
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Table 1 Baseline clinical characteristics.
DAT < 6months DAT > 6months p-Value
(n = 1149) (n = 157)
Age 66.50 67.18 0.135
Male, n (%) 773 (75) 118 (79) 0.676
BMI 23.74 24.02 0.548
Hypertension, n (%) 673 (65) 98 (66) 0.556
Diabetes mellitus, n (%) 415 (41) 66 (45) 0.451
Taking insulin 69 (6.8) 8 (5.4) 0.452
Hyperlipidemia, n (%) 378 (37) 53 (35) 0.375
Current smoking, n (%) 190 (19) 27 (18) 0.658
ACS, n (%) 72 (7.0) 10 (6.8) 0.921
Hemodialysis, n (%) 19 (1.8) 4 (2.7) 0.513
LVEF (%) 64.2 64.9 0.642
Previous MI, n (%) 164 (16) 27 (18) 0.656
Previous stroke, n (%) 64 (6.3) 15 (10) 0.109
Previous PTA, n (%) 17 (1.7) 3 (2.0) 0.809
Previous PCI, n (%) 371 (36) 59 (40) 0.642
Previous CABG, n (%) 22 (2.2) 2 (1.6) 0.475
LMCA, n (%) 22 (2.2) 11 (7.4) <0.001
Target of proximal LAD, n (%) 216 (21) 46 (31) 0.014
Multivessel stenting, n (%) 241 (24) 55 (37) 0.001
Lesion length (mm) 6.385 5.850 0.933
Maximal balloon diameter (mm) 3.098 3.185 0.027
Maximal inﬂation pressure (mmHg) 14.8 15.4 0.037
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aBMI: body mass index, ACS: acute coronary syndrome, LMCA: left
MI: myocardial infarction, PTA: percutaneous transluminal angiopl
bypass graft.
CI, 1.083—19.068; p = 0.039) were signiﬁcantly increased
(Fig. 1A—C).
During the follow-up period, 59 patients (4.6%) died of
cardiac causes. A total of 42 (3.2%) patients had an acute
MI, while 19 (1.5%) had deﬁnite stent thrombosis. There
was no signiﬁcant difference between the two groups in the
risk of the primary end points (stent thrombosis, non-fatal
MI, death from cardiac causes, death or MI) (Table 2 and
Fig. 2A—D).
Results of the logistic regression test for any bleeding are
shown in Fig. 2A. This result identiﬁed DAT >6months as one
of the factors that increased any bleeding complications.
However, there was no signiﬁcant difference in the rela-
tionship between any bleeding and age >65, male gender,
smoking, hypertension, and diabetes (Fig. 3).
To minimize the selection bias associated with the differ-
ence of the ratio of left main lesions, proximal left ascending
artery lesions, and multivessel lesions between two groups,
we excluded such high-risk patients and assessed the risk
of the similar composite end points. Table 3 shows DAT for
more than 6months was not signiﬁcantly more beneﬁcial
than monotherapy in reducing the risk of acute MI, stent
thrombosis, and death, although it was associated with an
increase bleeding complications for the low-risk patients
too.Discussion
This study has indicated that there were no signiﬁcant dif-
ferences in the onset of stent thrombosis, non-fatal MI, and
w
t
t
icoronary artery; LAD: left anterior descending coronary artery;
PCI: percutaneous coronary intervention; CABG: coronary artery
eath between the patient group which continued with DAT
or 6months or more, and the group that discontinued the
egimen within 6months.
There have been various reports on the duration of
reatment with DAT. The CREDO study [2] suggested that
dministration of clopidogrel for 1 year or more might
ecrease the onset of ischemic events in patients under-
oing PCI. The PCI-CURE study [3] indicated that the risk
f cardiovascular death, MI, and/or revascularization was
ower in the group with long-term clopidogrel administra-
ion after PCI compared with the placebo group. The stent
sed in the above-mentioned CREDO study and in the PCI-
URE study was a bare metal stent (BMS), which was not
ndicated for the treatment of acute coronary syndrome.
isenstein et al. [6] reported that continuous administra-
ion of clopidogrel reduced the incidence of acute MI at
2months after placement of a DES. However, the study
y Eisenstein et al. included only subjects who underwent
he ﬁrst PCI and excluded patients who received CABG and
hose with left main artery disease. On the other hand, this
tudy included patients who underwent PCI and/or CABG and
hose with left main artery disease; thus, the background of
atients differed between these reports.
The J-Cypher Registry [7] investigators, Kimura et al.
emonstrated that there were no differences in the 2-year
nd 3-year incidences of stent thrombosis between patients
ho discontinued thienopyridine alone and those who con-
inued with both aspirin and thienopyridine. Furthermore,
here have been some reports that a long-term double reg-
men following DES placement might not contribute to the
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Figure 1 (A) Survival rate for the end point of any bleeding. The x-axis represents days from baseline. The y-axis represents the
rate of survival. (B) Survival rate for the end point of major bleeding. The x-axis represents days from baseline. The y-axis represents
the rate of survival. (C) Survival rate for the end point of intracranial hemorrhage. The x-axis represents days from baseline. The
y-axis represents the rate of survival. DAT, dual antiplatelet therapy.
Table 2 Event rate for any bleedings from the indicated procedure during the follow-up period.
DAT < 6months (n = 1149) DAT > 6months (n = 157) p-Value
Stent thrombosis 15 (1.3%) 4 (2.6%) 0.197
Non fatal MI 36 (3.1%) 6 (3.8%) 0.469
Death 49 (4.3%) 10 (6.4%) 0.177
Death or non fatal MI 82 (7.1%) 15 (9.55%) 0.175
Table 3 Event rate for any bleedings from the indicated procedure during the follow-up period for low risk patients(after
excluding the patients of left main lesions, proximal left ascending artery lesions and multivessel lesions).
DAT < 6months (n = 669) DAT > 6months (n = 55) p-Value
Any bleedings 33 (4.9%) 14 (25%) 0.008
Major bleedings 24 (3.5%) 10 (18%) 0.001
Intracranial hemorrhage 5 (0.7%) 3 (5.4%) 0.02
Stent thrombosis 15 (2.1%) 4 (7.2%) 0.595
Non fatal MI 36 (5.3%) 6 (11%) 0.707
Death 49 (7.3%) 10 (18%) 0.062
Death or non fatal MI 82 (12%) 15 (27%) 0.072
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Figure 2 (A) Survival rate for the end point of stent thrombosis. The x-axis represents days from baseline. The y-axis represents
the rate of survival. (B) Survival rate for the end point of non-fatal myocardial infarction. The x-axis represents days from baseline.
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represents days from baseline. The y-axis represents the rate o
decrease in mortality and the incidence of acute MI [8,9].
In our study, long-term DAT for 6months or more has often
been applied to high-risk cases with proximal left anterior
descending artery disease, multiple coronary artery lesions,
and left main lesions. The difference between the results
of our study and such clinical studies may arise from differ-
ences in patient backgrounds.
On the other hand, our study demonstrated that DAT
for 6months or more was associated with an increase in
bleeding complications compared with the <6months regi-
men. Petersen et al. [10] reported that bleeding events after
DES placement occurred more frequently in the long-term
clopidogrel administration group. This study also reported a
similar ﬁnding. But the study by Petersen et al. included rel-
atively younger patients than the subjects in this study. Latib
et al. [11] reported that the prognostic predictive factors
s
r
i
s
aend point of death. The x-axis represents days from baseline.
d point of death or non-fatal myocardial infarction. The x-axis
vival. DAT, dual antiplatelet therapy.
or bleeding risk after DES placement included DAT and high
ge. The age differences of the subjects may be related to
he difference in the rate of bleeding events. Fujimoto et al.
12] reported the cases of acute coronary syndrome induced
y preoperative discontinuation of antiplatelet therapy in
he chronic phase after stent implantation. From these view-
oints, the duration of the administration of DAT after stent
lacement should be determined based on the individual risk
f ischemic and bleeding events.
In addition, inter-individual blood platelet responses to
ntiplatelet agents can vary. Tsukahara et al. [13] mea-
ured platelet activation by adenosine diphosphate and
eported that the higher platelet activation group exhib-
ted a higher risk of bleeding events and that bleeding risk
hould be stratiﬁed based on the measurement of platelet
ctivation. Compared with the previous large-scale clin-
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Age>65
Male Gender
DAT>6M
Smoking
Diabetes
Hypertension
T<6
0  
1.018(0.982-1.055) p=0.324
1.474(0.612-3.551)p=0.387
3.408(1.774-6.547) p<0.001
1.202(0.604-2.392)p=0.387
0.675(0.625-2.066)p=0.675
0.893(0.470-1.694)p=0.728
1  2  3  5  4  6  7  
Hazard ratio(95%CI) p-value
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igure 3 Hazard ratio (95% conﬁdence interval) for any bleed
cal studies, this study had a smaller number of cases
nd above-mentioned events, and no signiﬁcant differences
ere observed between groups.
Nevertheless, the usefulness of long-term administration
f DAT cannot be ruled out. This study was signiﬁcant as
t revealed that there were some problems with the long-
erm use of DAT after sirolimus-eluting stent placement,
ven when each case was closely studied. This study indi-
ated that DAT could be indicated for the treatment of
ower-risk patients, thereby excluding patients with acute
oronary syndrome, multiple coronary artery lesions, and
ultiple stent placement. Furthermore, higher risk patients
ould also receive DAT on condition that the regimen would
e discontinued after 6months. In cases of older patients,
ong-term DAT could increase bleeding risk and require dis-
ontinuation if necessary. As mentioned above, inadequate
uration of DAT after DES placement has not been fully inves-
igated. Therefore, a randomized study with a long-term
ollow-up investigation of this problem is anticipated.
tudy limitations
his study had certain limitations. The main limitation is
hat it is a non-randomized observational study and has the
ame disadvantages as any other observational study. Sec-
ndly, because the duration of DAT was left to the discretion
f the cardiologist, there might be a selection bias. Thirdly,
e did not measure platelet reactivity to antiplatelet agents
ssociated with the risk of bleeding in patients. Fourthly,
ince availability of medication data was limited, we did
ot assess the use of warfarin, therefore we did not evalu-
te the impact of anticoagulant therapy with DAT [14]. On
he other hand, we did not assess the use of proton pump
nhibitors, which reduce the incidence of gastrointestinal
esions compared with non-proton pump inhibitors [15].onclusion
n the present study, prolonged DAT for more than 6months
as not signiﬁcantly more beneﬁcial than aspirin monother-months
uring follow-up periods. DAT, dual antiplatelet therapy.
py in reducing the risk of the occurrence of acute MI,
tent thrombosis, and death, although it was associated with
n increase in bleeding complications for low-risk patients.
arger clinical trials will be necessary to resolve this prob-
em.
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